Headquartered in Coral Gables, FL·Fiscal year ends December·NASDAQ: RLMD·relmada.com
About Relmada Therapeutics
Relmada Therapeutics is a clinical-stage biotechnology company with no product revenue that develops therapies in oncology and central nervous system disorders. Its lead candidate, NDV-01, is a sustained-release intravesical co-formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer (NMIBC). NDV-01 forms a soft matrix in the bladder that releases drug for up to 10 days. It is designed as a ready-to-use, in-office treatment administered in under 5 minutes without anesthesia or specialized pharmacy preparation, targeting community urology practices. Its pending patent applications could provide protection to 2047 if issued. NDV-01 has shown high complete response rates in an ongoing Phase 2 study. It is headed into the FDA-aligned Phase 3 SPECTRUM program, which has two independent registrational pathways: second-line BCG-unresponsive high-risk NMIBC and adjuvant intermediate-risk NMIBC. The company's second candidate, sepranolone, is a GABA-A modulating steroid antagonist (isoallopregnanolone) being developed for compulsivity-related disorders. A Phase 2b trial in Prader-Willi Syndrome is planned. Relmada funds development through equity financing and holds about $202.1 million in cash and short-term investments, which management expects to fund operations through 2029. Updated
Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, while Relmada Therapeutics (RLMD) sits at $7.17, also up 61.1% Both moves were absolutely eye-popping, but…
Pre-Market Stock Futures: Futures are trading higher as we get ready to start a holiday-shortened trading week after an outstanding triple-witching Friday rally that may have kicked the “Santa Claus” rally into…
Relmada Therapeutics is a clinical-stage biotechnology company with no product revenue that develops therapies in oncology and central nervous system disorders. Its lead candidate, NDV-01, is a sustained-release intravesical co-formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer (NMIBC).
What is the RLMD stock price target?
The Wall Street consensus 12-month price target for RLMD is $10.75.